Moderna Cancer Vaccine Phase 3 Success: AI-Powered Neoantigens
BoWang87 · x · 2026-08-20
Moderna and Merck announced positive Phase 3 results for their individualized mRNA cancer vaccine (INTerpath-001) in resected melanoma (1,137 patients). This is the first successful Phase 3 trial for individualized neoantigen therapy.
Pipeline:
- Surgical resection.
- Whole exome + RNA sequencing.
- ML algorithm identifies somatic mutations and predicts which are immunogenic (displayed on cell surface to trigger T-cell response).
- mRNA encoding up to 34 patient-specific targets.
- Manufactured and shipped in 8 weeks.
Key Validations:
- ML Prediction Works: Tumor-specific neoantigen prediction validated in a large-scale blinded trial.
- Manufacturing Feasibility: 8-week personalized mRNA manufacturing is operationally real.
- Additive Effect: Combination with PD-1 blockade (Keytruda) showed additive benefit, not redundancy.
More from Apps
- Robinhood's new Platinum card includes $250 annual Waymo ride credit — reed · 2026-10-16
- ChatGPT's missing UTM tags confirmed as a bug, traffic attribution fully restored — lilyraynyc · 2026-10-16
- Tolan hailed as the AI product Steve Jobs would have built, per viral essay — ajaymehta · 2026-10-16
- Design Studio Runs Agentic Workflows on FLORA Canvas, From Prototype to Shipped Site — round · 2026-10-16
- AI agents have a 'normal-people problem': most users won't hand over their lives — examachine · 2026-10-16
- She planned a Napa trip with an AI planner, changed everything last minute — 'at least the car drove itself' — katieruthmishra · 2026-10-16